Podocyte Expression of Membrane Transporters Involved in Puromycin Aminonucleoside-Mediated Injury

Cristina Zennaro1, Maria Pia Rastaldi2, Lorella Pascolo6, Marco Stebel3, Elisa Trevisan3, Mary Artero4, Claudio Tiribelli1,5, Vittorio Di Maso1, Michele Carraro1*

1 Department of Medical, Surgery and Health Sciences, Università degli Studi di Trieste, Trieste, Italy, 2 Renal Research Laboratory, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico & Fondazione D’Amico per la Ricerca sulle Malattie Renali, Milano, Italy, 3 Department of Life Sciences, Università degli Studi di Trieste, Trieste, Italy, 4 Azienda Ospedaliero-Universitaria Ospedali di Riuniti di Trieste, Trieste, Italy, 5 Liver Research Center, AREA Science Park, Trieste, Italy, 6 IRCCS Burlo Garofolo Istituto per la Cura a Carattere Scientifico Materno Infantile, Trieste, Italy

Abstract

Several complex mechanisms contribute to the maintenance of the intricate ramified morphology of glomerular podocytes and to interactions with neighboring cells and the underlying basement membrane. Recently, components of small molecule transporter families have been found in the podocyte membrane, but expression and function of membrane transporters in podocytes is largely unexplored. To investigate this complex field of investigation, we used two molecules which are known substrates of membrane transporters, namely Penicillin G and Puromycin Aminonucleoside (PA). We observed that Penicillin G pre-administration prevented both in vitro and in vivo podocyte damage caused by PA, suggesting the engagement of the same membrane transporters by the two molecules. Indeed, we found that podocytes express a series of transporters which are known to be used by Penicillin G, such as members of the Organic Anion Transporter Polypeptides (OATP/Oatp) family of influx transporters, and P-glycoprotein, a member of the MultiDrug Resistance (MDR) efflux transporter family. Expression of OATP/Oatp transporters was modified by PA treatment. Similarly, in vitro PA treatment increased mRNA and protein expression of P-glycoprotein, as well as its activity, confirming the engagement of the molecule upon PA administration. In summary, we have characterized some of the small molecule transporters present at the podocyte membrane, focusing on those used by PA to enter and exit the cell. Further investigation will be needed to understand precisely the role of these transporter families in maintaining podocyte homeostasis and in the pathogenesis of podocyte injury.

Introduction

Pathology of the podocyte underlies several glomerular diseases, the most severe being local segmental glomerulosclerosis, which is clinically characterized by heavy proteinuria or nephrotic syndrome and frequently progresses to renal insufficiency. The cellular mechanisms resulting in proteinuria are not completely understood, and thus the description of pathways leading to podocyte damage and repair are relevant to the identification of novel treatment strategies.

The membrane transport system, known as a major transmembrane component involved in the movement of ions, small molecules, and drugs, has been extensively studied in some organs and cellular systems, such as the intestine, the liver, and the blood-brain barrier. In the kidney, several members of the main membrane transporter families have been described in the renal tubule in the context of ion and drug transport [1]. Recently, two transporters with broad specificity for small molecules have been identified in mouse podocytes in relation to drug clearance [2,3].

Podocytes are highly differentiated cells with a complex ramified structure, the maintenance of which requires coordinated trafficking from the extracellular to the intracellular compartment, similar to that operating in other highly ramified cells, such as neurons [4]. Small molecule transporters constitutively expressed in the podocyte contribute to maintain the cellular structure and barrier function, possibly by interacting with endogenous substrates and metabolites; and they could also be involved in the uptake and efflux of drugs in these cells.

A better understanding of transport mechanisms in podocytes is needed to explain in part some functions of these cells and to conform to the recently issued FDA draft guidance which includes the recommendation to increase knowledge about drug transport and metabolism (www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf).

With this background, we performed experiments using Penicillin G, a well-known beta-lactam antibiotic, which is the substrate of several transporter families that have been fully characterized in other cellular models [5]. The antibiotic was used in the context of podocyte injury by puromycin aminonucleoside (PA), a small molecule that uses membrane transporters to enter the cell [6], and induces podocyte damage which mimics lesions of glomerulosclerosis.

Citation: Zennaro C, Rastaldi MP, Pascolo L, Stebel M, Trevisan E, et al. (2013) Podocyte Expression of Membrane Transporters Involved in Puromycin Aminonucleoside-Mediated Injury. PLoS ONE 8(6): e66159. doi:10.1371/journal.pone.0066159

Editor: Hendrik W. van Veen, University of Cambridge, United Kingdom

Received February 1, 2013; Accepted May 2, 2013; Published June 20, 2013

Copyright: © 2013 Zennaro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grants from “Fondazione la Nuova Speranza onlus Lotta alla Glomerulosi Focale. Rho (Milano, Italy)”, “Fondazione Benefica Kathleen Foreman Casali, Trieste, Italy” and by “Renal Child Foundation, G. Gaslini Children Hospital, Genova, Italy”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: m.carraro@fmc.units.it
minimal change disease or focal segmental glomerulosclerosis, with appearance of severe proteinuria when injected in rats [7].

We reasoned that if Penicillin G engaged transporters at the podocyte surface, the entrance and the subsequent activity of PA would be blocked, providing evidence that the two molecules use the same membrane transporter families in podocytes.

Materials and Methods

Animals and experimental design

Young male Sprague-Dawley rats (n = 30) weighing 230–250 g housed at the University of Trieste (Italy) animal facility were randomly divided into three control groups and three experimental groups (5 animals per each group, see Table 1). The rats were housed two or three per cage in an air-conditioned, light-controlled environment, and all animals had unrestricted access to food and water.

A committee of the Italian Health Ministry approved the experimental protocol (prot. n 166-date: April, 8, 2005), in compliance with Italian regulation (D.L.vo 116/92). General anaesthesia was provided with an IP injection of 2 ml Avertin 2% and 100 ul Xilazine 2%. Local anaesthesia was provided with 100 ul of Lidocaine 2% in the site of incision and all efforts were made to minimize suffering.

In the experimental groups rats received a single intravenous injection (5 mg/100 g body weight) of puromycin aminonucleoside (PA) (Sigma) in the femoral vein, whereas rats in the control groups were treated with the same volume (1 ml) of saline. Pre-treatment with Penicillin G (Penicillin G sodium salt, Sigma), at dosages of 12,500 IU or 15,000 IU was performed 10 minutes before the injection of PA or saline in the same femoral vein.

A 24h urine collection was obtained on day –1 before PA injection, then on day 5 and 10.

On day 10 the animals were sacrificed, and a blood sample was collected for creatinine and serum albumin analysis. One kidney was immediately excised to isolate glomeruli for the albumin permeability tests (Palb), and the other kidney was used for histological analyses. Creatinine and serum albumin were determined by an autoanalyzer technique (Hitachi 717, Tokyo), and proteinuria was assessed by the Comassie Brilliant Blue assay.

Glomerular morphometric analysis

Kidney tissue was fixed in formalin and embedded in paraffin using standard techniques. 4 um-thick sections were deparaffinized, hydrated and stained with periodic acid-Schiff (PAS). Twenty glomeruli per animal were analyzed. Digital images were taken using an upright microscope (Olympus Italia, Segrate, Milan, Italy) equipped with a digital camera. The mean area of each glomerulus was measured by manually tracing the glomerular outline on 200X acquired images, and measured off-line by a video-based image analysis program (Sigma Scan Pro, Jandel Scientific Software).

The convective glomerular albumin permeability assay (Palb)

The method for measuring glomerular albumin permeability, adapted from the original description by Savin [8], allows the study of the glomerular response to various mediators in the absence of systemic humoral, hemodynamic, or rheologic forces [9], and has been applied extensively by our group to analyze glomerular damage [10,11,12].

Glomeruli were isolated by sieving in BSA solution; during the sieving process, they are stripped of Bowman’s capsule, tubules, and associated blood vessels. In this work, two sets of experiments were performed, one comprising isolated glomeruli from control and experimental rats, and the other conducted on glomeruli isolated from untreated, healthy male Sprague Dawley rats. Glomeruli from experimental rats underwent directly Palb determination. Glomeruli from untreated animals were instead incubated with PA (0.5 ug/ml to 10.0 ug/ml) or saline for 10 minutes at 37°C. In this set of experiments Penicillin G (50 IU/ml to 700 IU/ml) was added to the incubation medium 10 min before or 10 min after PA incubation, and glomeruli were carefully washed to avoid any possible extracellular interaction between the two drugs. Penicillin G alone at the same concentration was used as a control.

Isolated glomeruli adhesion assay

Isolated glomeruli from healthy young male Sprague Dawley rats were centrifuged at 800 rpm for 2 minutes for fragment elimination. The pellet was resuspended in medium and plated on type IV collagen-coated 24 multi-well plastic plates (100 glomeruli/well). After pre-incubation for 30 minutes with Penicillin G (500 IU/ml or 700 IU/ml, the glomeruli were carefully washed and treated with PA (10, 5 and 2.5 ug/ml) or an equal volume of 500 IU/ml or 700 IU/ml) was added to the incubation medium 10 min before or 10 min after PA incubation, and glomeruli were carefully washed to avoid any possible extracellular interaction between the two drugs. Penicillin G alone at the same concentration was used as a control.

Podocyte cultures

We used a human immortalized cell line, following the procedure originally described by Dobbler at al. [13], with minor modifications. Differentiated podocytes were cultured in Dulbecco’s modified Eagle’s high glucose medium (DMEM) containing 10% fetal bovine serum (FBS-Euroclone Ltd, Wetherby West Yorkshire, UK).

Table 1. Experimental animal groups.

| Group          | Treatment                           |
|----------------|-------------------------------------|
| Control 1 - saline | Saline solution                     |
| Control 2 - PEN 12,500 | Penicillin G 12,500 Units + saline |
| Control 3 - PEN 15,000 | Penicillin G 15,000 Units + saline |
| Experimental 1 - PA  | Puromycin aminonucleoside (5 mg/100 g body weight) |
| Experimental 2 - PEN (12,500) + PA | Penicillin G 12,500 Unit + PA (5 mg/100 g body weight) |
| Experimental 3 - PEN (15,000) + PA | Penicillin G 15,000 Unit + PA (5 mg/100 g body weight) |
For primary podocyte cultures, glomeruli from healthy young male Sprague Dawley rats were isolated by sieving, then seeded in culture flasks pre-coated with collagen IV (Sigma-Aldrich) in medium containing Dulbecco’s modified Eagle/F12 medium (DMEM/F12) supplemented with 10% FBS, 5 μg/ml transferrin, 10 mM glutamine (Sigma-Aldrich). After four days first passage podocytes (5 × 10^5 cells/ml) were incubated with 10 μg/ml Bocillin for 20 minutes. Cells were washed with cool PBS and resuspended in Penicillin-glutamine (100 μg/ml Penicillin, 100 μg/ml glutamine) and incubated with Bocillin fluorescence in live cells. Bocillin TM 650-665 Penicillin is a synthesized compound from Penicillin V and the Bodipy 650/655 dye. To confirm the cellular uptake of Penicillin, we performed a flow cytometry analysis. After trypsinization, podocytes (5 × 10^6 cells/ml) were incubated with 10 μg/ml Bocillin for 20 minutes. Cells were washed with cool PBS and resuspended in Penicillin-free medium. At the indicated times 1.5 × 10^6 cells were analyzed by flow cytometry (Beckton Dickinson FACS Elite) and untreated podocytes were used as control.

**MTT assay**

Human immortalized podocyte proliferation was assessed by the methylthiazol tetrazolium (MTT) assay (Sigma Company, St. Louis, MO, USA), according to the manufacturer’s instructions. This non-radioactive cell proliferation assay identifies living cells based on the cellular conversion of a tetrazolium salt into a formazan product, a chromophore which can be quantified by ELISA. Briefly, cells were plated onto 96 multi-well plates (8000 cells/well) and allowed to adhere overnight without antibiotic. Podocytes were exposed to PA alone (10, 5 and 2.5 μg/ml), Penicillin G alone (10, 50, 500 and 700 Units/ml) or PA and Penicillin G at the same concentration, in medium containing no cells (but containing medium and MTT over the incubation period) were used to blank the plate reader. The results were the means of three separate experiments, expressed as absorbance at 570 nm.

**Transporter gene expression study**

Gene expression of various Penicillin G membrane transporters, selected according to the data reported for other cell types, were analyzed in human and rat podocytes. Specifically, we investigated organic anion transporters of the OATP family, one transporter of the OAT family, the peptide transporters PEPT1 and PEPT2, and the OATP-B family transporters.

**Table 2. Investigated human transporters.**

| Type PCR | GBN | Protein and Gene Symbol | Primer pair | TA (°C) | Amplif. region Length(bp) |
|----------|-----|-------------------------|-------------|--------|--------------------------|
| RT-PCR/QRT-PCR | NM 134431 | OATP1A2, (SLC21A2) OATP-A | (F) 5’-CCATTGGAAACGGGAAATAAAC-3’ (R) 5’-TCTTCTCAGATTCTACACACCTCA-3’ | 60° | 2136–2351 216 |
|          | NM 007256 | OATP2B1, (SLCO281) OATP-B | (F) 5’-GGGCAAAGGACAGGTCTTCTACAC-3’ (R) 5’-AGGAAGGGCACACCAAGATG-3’ | 60° | 1851–1958 108 |
|          | NM 006446 | OATP1B1, (SLCO1B1) OATP-C | (F) 5’T-AAGGCTGATATAATTGGAAGTC-3’(R) 5’-ACAGCACAGAACATACGAAATTGG-3’ | 60° | 1250–1382 133 |
|          | NM 013272 | OATP3A1, (SLCO3A1) OATP-D | (F) 5’-AGGCTCTGGACCCCCATCG-3’(R) 5’-CCCGTGAGATCCCGTAGA-3’ | 60° | 1582–1716 135 |
|          | NM 016354 | OATP4A1, (SLC21A2) OATP-E | (F) 5’-CCAGGATTGAAGGAAAGCAG-3’(R) 5’-AGGAGGCCAGATGAGAGAGG-3’ | 60° | 1253–1341 89 |
|          | NM 004254 | OAT3 (SLC22A8) | (F) 5’-CCACAGCTCATACCGACAAACA-3’(R) 5’-AGGGCGGCTGTAACCCGTA-3’ | 60° | 1448–1584 137 |
|          | NM 00927 | MDR1 (ABCB1) | (F) 5’T-GTCTCAGACAGGATGTGAGTGG-3’ (R) 5’-AATTACAGAAGGACTGGGAAC-3’ | 60° | 2808-2926 122 |
|          | NM 005073 | PEPT1 (SLC15A1) | (F) 5’-CACCCTCTGAAGAAGATGGGAA-3’(R) 5’-GGGAAGCCTGAAAGATTATGTCG-3’ | 60° | 1121-1225 105 |
|          | NM 021082 | PEPT2 (SLC15A2) | (F) 5’T-TTGTGTTCTCTACACTGAGGACT-3’ (R) 5’-CTGCTTTCTGATCTACCTACACAT-3’ | 60° | 1453-1563 111 |
|          | NM 002046 | GAPDH | (F) 5’-CCATCATCATTCTTCCAGGAG-3’(R) 5’-CTTCCTCAGTGTGTTGGAAGAGC-3’ | 60° | 319-423 105 |
| Only RT-PCR | NM 005073 | PEPT1 (SLC15A1) | (F) 5’T-CAGGCTCAGGAGGACTG-3’ (R) 5’-GAAGGAGGCCAGATGAGAGG-3’ | 55° | 4-283 279 |
|          | NM 021082 | PEPT2 (SLC15A2) | (F) 5’-GAAGGCTCCACACATCAGTG-3’(R) 5’-GCAAGGACATACACCAAGG-3’ | 60° | 245- 525 280 |

GBN Gene Bank Number; TA Annealing Temperature.
doi:10.1371/journal.pone.0066159.t001
the efflux transporter P-glycoprotein. As a control, the same transporters were analyzed in neuronal (SH-SY5Y neuroblastoma) and intestinal cell lines (Caco2 colon cancer cells), as well as in whole organ mRNA extracts (intestine, liver, and kidney).

Total RNA from cells was extracted using the Invitrogen Pure Link TM Micro-to-midi Total RNA Purification System. RNA concentrations were determined using Nanodrop ND 1000 (Cell Euroclone Italy). One microgram of total RNA was reverse transcribed using MMLV reverse transcriptase (Applied Biosystems). The analyses were performed by transcriptase-polymerase chain reaction (RT-PCR) and quantitative Real Time RT-PCR (QRT-PCR). Primers and annealing temperatures are reported in Table 2 and Table 3; GAPDH and beta-actin were used as housekeeping genes, as appropriate.

For the QRT-PCR the amplification steps were: pre-denaturation at 95°C for 10 min, 40 cycles of amplification with denaturation at 95°C for 15 s, annealing at proper temperature for 60s and extension at 72°C for 30 s. A final extension at 72°C for 10 min and a dissociation stage (95/60/95°C for 60s and extension at 72°C) were then added.

RT-PCR conditions were described by Tramoni et al. [1] and Engel et al. [14]. For the RT-PCR the ethidium bromide-stained agarose gel was visualized using a gel documentation system (PhotoDoc-it, Imaging System Digital, UVO Cambridge UK).

Transporter immunofluorescence analysis

An indirect immunofluorescence method was utilized on primary cells fixed in aceton or paraformaldehyde, depending on the subsequent application, and plated on Thermox plastic coverslips (Nunc, Rochester, NY, USA). F-actin was detected directly by phalloidin-FITC or phalloidin-rhodamine (Sigma). Mouse monoclonal anti-[C219] P-glycoprotein (Abcam), rabbit anti-synaptopodin and rabbit anti-vinculin (Sigma) were the primary antibodies used for the study. As secondary fluorescent-labeled antibodies, we used FITC-conjugated goat anti-mouse IgG (Pierce), FITC-conjugated goat anti-rabbit IgG (DAKO A/S, Denmark) and Alexa Fluor 488 donkey anti-rabbit (Invitrogen). Slides were examined by a fluorescence microscope (Leica Microsystems, Germany). Controls with no primary antibody showed no fluorescence labelling. P-glycoprotein expression was investigated using the fluorescence probe Rho123 (Sigma Company, St. Louis, USA) in an efflux assay, as described by Chen et al. [15]. After PA

Table 3. Investigated rat transporters.

| Type PCR | GNB | Protein and Gene Symbol | Primer pair | TA (°C) | Amplif. region | Length (bp) |
|----------|-----|-------------------------|-------------|--------|----------------|------------|
| RT-PCR   | AF257746.1 | Mdr1a (abc1a) | (F) 5' -GGCGACATGCATCAGACGCCC-3' (R) 5' - GGACGAGCTCAT TGGCAAGCGCT-3' | 65 | 2081-2531 | 450 |
| NM 012623.2 | Mdr1b(abc1b) | (F) 5' - AGTGACACTGCTGGCTCTGGA-3' (R) 5' - CAAACACTGGTTGATTGAC-3' | 62 | 1965-2210 | 245 |
| D50664.1 | PepT1 (Slc15a1) | (F) 5' - GCACCTTAACAGGATAGATACC-3' (R) 5' - ACGGGAAACAGAAACATCAGTGG-3' | 60 | 1529-2018 | 489 |
| NM 031672.1 | PepT2 (Slc15a2) | (F) 5' - GAGCTATCTCAGAGCTGGTCAAGG-3' (R) 5' - CCAACTGCGAACGTTCAACACCCGGC-3' | 62 | 1667-2147 | 480 |
| AB17446.1 | Oat3 (Slc22a8) | (F) 5' - CATCCTGGCCTGTCATGTCG-3' (R) 5' - TACGTTGGGATGATGACTTGTG-3' | 55 | 108-1792 | 1684 |
| NM 030838.1 | Oatp3 (Slco1a5) | (F) 5' - CGCTTGGGATGAGATGATTACGC-3' (R) 5' - ATGAGACAGTGGGCTGAGA-3' | 57 | 1870-2482 | 612 |
| NM 133608.2 | OatpE (Slco4a1) | (F) 5' - CAGTGGGATGAGATGATTACGC-3' (R) 5' - GATGGAGCAGTGATGATGATG-3' | 57 | 181-816 | 635 |
| NM 031144 | beta-actin | (F) 5' - GAGCGACATGGAGATGATTACGC-3' (R) 5' - GAGATGGAGCAGTGATGATGATG-3' | 58 | 298-790 | 492 |
| QRT-PCR   | NM 017111.1 | Oatp1 (Oatp1a1) | (F) 5' - CTGAGCTCTTGCTCTTTCCATG-3' (R) 5' - GCTTTCCTCCTCCTGCGG-3' | 55 | 1897-2000 | 103 |
| U95011 | Oatp2 (Oatp1a4) | (F) 5' - TGATCTACCATCCTGAGCTATGC-3' (R) 5' - TGTCATACATCCTGAGCTATGC-3' | 55 | 1891-1995 | 104 |
| NM 133608.2 | OatpE (Slco4a1) | (F) 5' - CTGAGCTCTTGCTCTTTCCATG-3' (R) 5' - GCTTTCCTCCTCCTGCGG-3' | 60 | 1874-1926 | 52 |
| NM 00100204.1 | Oatp4c1 | (F) 5' - CAAGTTGTTGGATTGTAATAAGGCCTAGT-3' (R) 5' - AGACAAAGCCCAAGAGGAGATG-3' | 58 | 338-465 | 127 |
| AY5825225 | Mdr1a (abc1a) | (F) 5' - AATCCACCTCGGAAAAGATCC-3' (R) 5' - TTATTTAACCTCGGAAAAGATCC-3' | 60 | 1973-2089 | 116 |
| BC107560 | Mdr1b (abc1b) | (F) 5' - CTGAGCTCTTGCTCTTTCCATG-3' (R) 5' - GCTTTCCTCCTCCTGCGG-3' | 53 | 508-634 | 126 |
| X02231.1 | GAPDH | (F) 5' - TAAAAGGTAGCTGGGCTACACT-3' (R) 5' - TATCTTGGGAGGAGTCATGG-3' | 60 | 873-1073 | 200 |

GBN, Gene Bank Number; TA, Annealing Temperature; doi:10.1371/journal.pone.0066159.t002
incubation for 48 hours, human podocytes were tested for Rho123 efflux rate. Podocytes (5 × 10^5 cells/ml) were washed and stained with 200 ng/ml Rho123 for 20 minutes. Cells were washed again with cool PBS and resuspended in Rho123-free medium for 60 min at 37°C to allow for Rho 123 efflux. At the indicated times 1.5 × 10^3 cells were taken for analysis on a flow cytometer (Beckton Dickinson FACS Elite). Podocytes not treated with Rho123 were used as control. Cyclosporine A (CSA 0.1, 0.5 or 1 μM) was used to inhibit P-glycoprotein activity and added to the Rho123-free medium after staining to prevent probe efflux. A minimum of 15,000 gated events were recorded for each sample.

Membrane transporters’ blockade

As transport inhibitors we used cyclosporine A and rifampicin (Sigma Company, St Louis, UAS). While rifampicin blocks the OATPs/Oatps transporters, cyclosporine A exerts its inhibiting activity on both OATPs/Oatps and P-glycoprotein. The two inhibitors were alternatively utilized in combination with fluorescent penicillin. More in detail, to assess effects on OATPs/Oatps activity, cells were first treated for 30 minutes with Cyclosporine 1 μM, or rifampicin 1 μM–10 μM. Then, fluorescence penicillin (50 μg/ml) was added for 30 minutes; after washes, live cells were imaged.

To study P-glycoprotein blockade, cells were first incubated with fluorescent penicillin 50 μg/ml for 30 min, and images were taken after addition of cyclosporine 1 μM for 30 min.

Fluorescence intensity was measured on 100 cells per condition by image analysis software (Image ProPlus 6.3 Software) and results were expressed as relative change of intensity compared to controls arbitrarily given a value of 1. Experiments were repeated trice per each condition.

Figure 1. Albumin permeability (Palb) assay in isolated glomeruli from healthy rats. (a) Palb increases after PA incubation (**P < 0.001 vs NT - untreated glomeruli), and the increase is completely blocked (b) by preincubation with Penicillin G (PEN), when 700 Units/ml are added to the cells and is reduced by 500 Units/ml (**P < 0.001 and ***P < 0.0001 vs. corresponding PA concentration). (c) The incubation with Penicillin G alone does not alter glomerular albumin permeability, and (d) treatment with Penicillin G after PA incubation does not protect glomerular integrity (** P < 0.001 vs NT). Palb values are expressed as mean ± standard deviation. 25 glomeruli were analyzed per each point.

doi:10.1371/journal.pone.0066159.g001
Statistical analysis

Data are presented as mean ± SD or mean ± SEM. Comparison of means was performed by ANOVA test.

Results

Penicillin G pre-treatment in isolated glomeruli before PA incubation

PA incubation at concentrations ranging from 10 μg/ml to 0.6 μg/ml increased Pₐₙ of isolated healthy glomeruli (Fig 1a). The effect was abolished in a dose-dependent manner by 15 min pre-incubation with Penicillin G and complete inhibition appeared at a concentration of 700 IU/ml, but a significant effect was already present at a concentration of 500 IU/ml (Fig 1b).

Incubation of glomeruli with Penicillin G alone did not affect Pₐₙ (Fig 1c). When isolated glomeruli were exposed to PA (10 μg/ml) before Penicillin (700 Unit/ml), Pₐₙ remained elevated (0.75±0.05 vs. 0.89±0.20) (Fig 1d), supporting the hypothesis that the Penicillin effect is exerted by blocking PA entrance into the cell.

Effect of PA and Penicillin G on glomerular adhesion and cellular outgrowth on collagen IV substrate

In control conditions 85±5% of isolated glomeruli adhered to the collagen IV substrate, and a cellular outgrowth was observed around the glomerular structure (Fig 2A-a). The incubation with PA alone diminished the number of adhered glomeruli at all PA concentrations compared to control; the outgrowth from glomeruli was limited, and the cellular morphology was altered (Fig 2A-b, 2B).

A complete inhibition of the PA effect was present when Penicillin G 700 IU/ml was pre-added, i.e. the number of attached glomeruli and the outgrowth from glomeruli were similar to the control experiment (Fig 2A-c, 2B). A partial inhibition of PA effect was observed for Penicillin G 500 IU/ml (Fig 2B). Glomeruli treated only with Penicillin at the same concentrations demonstrated a behavior similar to the control (data not shown).

Penicillin G prevents PA-induced podocyte damage

A preliminary time-course study was first conducted with human podocytes incubated with PA for different periods (12, 24, 32 and 48 hours); decreased viability was observed after 48 hours of incubation; therefore, this time point was selected for further investigation.

Penicillin G alone did not affect cell viability as compared to medium alone, whereas PA alone diminished viability by about 50% (Fig 3a). Pre-incubation with Penicillin G prevented partially or completely the decrease of viable cells induced by PA; the effect was statistically significant at the concentration of 700 IU/ml of Penicillin G (Fig 3a).

As illustrated in Figure 3B, in control condition actin stress fibers were prominent in the podocyte cell body. The focal adhesion molecule vinculin showed a peripheral and regularly distributed pattern of expression and co-localized with actin.
These features were dose-dependently lost after PA incubation (2.5 and 10 ug/ml) for 48h, whereas preincubation with Penicillin G partially (PA 10 ug/ml) or completely (PA 2.5 ug/ml) prevented PA-induced cytoskeletal remodeling.

Internalization of fluorescent Penicillin in human podocytes

The above described results suggest that Penicillin G may block PA entry by engaging membrane transporters. If so, it would be possible to find Penicillin G inside the cell. To test this hypothesis, cells were incubated with the Penicillin fluorescent analogue Bocillin. Fluorescent intracellular puncta evenly distributed throughout the cytoplasm (Fig. 4a,b,c) and in the cell processes (Fig 4d, e) were clearly observed after 30 minutes incubation. Intracellular fluorescence was detected in 100% of cells also by flow cytometry (Fig 4f).

Penicillin G pre-treatment in the PA rat model

As expected [16], a single injection of PA in three-month old Sprague-Dawley rats caused proteinuria by day 10 (52.41±19.51 vs. 9.86±2.87 mg/dl), soon accompanied by decreased serum albumin (1.68±0.26 vs. 3.12±0.45 g/dl, Table 4). Pretreatment with either 12,500 or 15,000 IU Penicillin G reduced proteinuria (14.18±8.3 and 15.14±12.25 vs. 52.41±19.51 mg/dl), and was
associated with increased serum albumin (Table 4). Penicillin pre-treatment also affected the kidney-to-body weight ratio and glomerular size. Control animals, receiving Penicillin G followed by saline, did not differ from saline-injected controls (Table 4). The analysis of Palb on isolated glomeruli from animals sacrificed at the end of the study (day 10) showed that Penicillin G pre-treatment preserved glomerular albumin permeability in the normal range and demonstrated a strict correlation with the urinary protein values observed in the in vivo experiments (Fig 5).

Podocytes express the mRNA of species-specific membrane transporters

The inhibitory effect of Penicillin G on PA-induced glomerular injury both in vitro and in vivo, and the entrance of Penicillin into the cell, suggested the possible engagement by Penicillin of the same membrane transporters used by PA. Therefore, RT-PCR and quantitative RT-PCR experiments were performed to analyze components of the membrane transport families that have been associated with Penicillin G membrane transport in other cell systems.

As summarized in Fig 6, human podocytes expressed OATP-A, OATP-B, OATP-D and OATP-E from the OATP family; in contrast, OATP-C (liver specific transporters), OAT3 and PEPT1

**Table 4.** Variables (mean ± standard deviation) at the end of the animal study.

| Analysis                  | Control 1    | Experimental 1 | Experimental 2 | Experimental 3 | Control 2    | Control 3    |
|---------------------------|--------------|----------------|----------------|----------------|--------------|--------------|
| Proteinuria (mg/24h)      | 9.86±2.87    | 2.41±19.51**   | 14.18±8.3      | 15.14±12.25    | 12.83±8.04   | 13.75±5.05   |
| Serum albumin (g/dl)      | 3.12±0.45    | 1.68±0.26**    | 2.23±0.95      | 2.73±0.68      | 3.35±0.27    | 3.23±0.25    |
| Serum creatinine (mg/dl)  | 0.25±0.02    | 0.37±0.13      | 0.32±0.02      | 0.29±0.64      | 0.26±0.03    | 0.28±0.15    |
| Renal weight (mg/g body weight) | 3.02±0.13   | 5.08±1.21**    | 3.16±0.10      | 3.93±0.95      | 3.25±0.11    | 3.61±0.27    |
| Glomerular area (µm²×10³) | 7.8±0.5      | 10.6±1.7**     | 8.8±0.7        | 8.3±0.7        | 7.05±1.02    | 7.36±0.80    |
| Glomerular permeability (Palb) | 0.03±0.03    | 0.71±0.13**    | 0.16±0.24      | 0.07±0.23      | 0.07±0.26    | 0.02±0.14    |

Control 1, saline; Control 2, PEN 12,500; Control 3, PEN 15,000; Experimental 1, PA; Experimental 2, PEN(12,500)+PA; Experimental 3, PEN (15,000)+PA.

PA, puromycin aminonucleoside; PEN Penicillin G; **P<0.005 compared with control 1; ***P<0.05 compared with control 1; ****P<0.0001 compared with control 1.

doi:10.1371/journal.pone.0066159.t003
were not detected, and PEPT2 showed a low expression level (Fig 6a, b). In primary rat podocytes, we studied the OATP transporter family (Oatp1, Oatp2, Oatp3, Oatp4c1), one member of the Oat family (Oat3), and the peptide transporters PepT1 and PepT2 (Fig 6c,d). In agreement with the results obtained in human cells, we found expression of all genes that codify for Oatp transporters but Oatp3, and absence of the other analyzed membrane transporters.

Considering the high expression of the OATP transporters, we searched for their possible variation induced by PA. Though a significant variation was only found for Oatp2, that was increased in rat podocytes after PA treatment, also other transporters exhibited expression changes, particularly OATP-A in human cells and Oatp1 in rat podocytes (Fig 7a,b,c).

Podocytes express a specific efflux transporter P-glycoprotein
The gene expression of OATP/Oatp influx transporters on the podocyte surface implies the co-expression of efflux membrane transporters, such as P-glycoprotein, as described by Kim [17].

Our results show that the P-glycoprotein transporter gene (MDR1) is indeed expressed by human podocytes (Fig 8a), and increases in PA-treated cells, particularly after 48 hours (P<0.001, Fig 8c).

Correspondingly, the rat MDR1 homologues, Mdr1a and Mdr1b, are both expressed in rat podocytes (Fig 8b), where 48 hour PA incubation was able to increase Mdr1a expression (Fig 8d).

P-glycoprotein analysis by immunofluorescence confirmed the increased expression after 48 hour PA incubation (Fig 9 a,b,c), when PA also caused remodeling of the podocyte cytoskeleton, as shown by the alteration of synaptopodin (Fig 9c), and the almost complete disappearance of actin stress fibers (Fig 9g).

To establish if P-glycoprotein expressed by podocytes was functionally active, and if its activity could be modified by PA, we used its specific fluorescent substrate Rho 123 (Fig 10) and the specific inhibitor cyclosporine A (CSA) [15]. In control experiments, after Rho 123 incubation and replacement with Rho 123-free medium, mean fluorescence intensity decreased by approximately 35%, indicating Rho 123 efflux from the cells (Fig 10a). PA incubation caused an increase of Rho 123 efflux, as shown by further reduction of fluorescence as compared to the control cells (Fig. 10b), whereas CSA consistently abolished the efflux of the substrate.

**Figure 5. PA rat model.** Panel a) shows the results of Palb values in glomeruli isolated from rats treated with PA compared to controls and Penicillin-injected animals. Palb values are expressed as mean ± SD, and 25 glomeruli were evaluated per each animal (5 rats per group). ### P<0.00001 vs. controls **P<0.001 vs. PA model *** P<0.0001 vs. PA model. Panel b) displays the urinary protein determination obtained from the same groups of rats. Values are expressed as mean ± SD. # # # P<0.005 vs. controls.
doi:10.1371/journal.pone.0066159.g005
Effects of transport blockade

Confirming the use of OATPs/Oatps by penicillin G to enter the cell, blockade of these transporters by either cyclosporine or rifampicin, inhibited the entry of fluorescent penicillin (Figure 11a,b) into podocytes.

When cyclosporine was added after penicillin internalization was completed, P-glycoprotein blockade was confirmed by persistent cell fluorescence, whereas untreated cells were mostly devoid of penicillin (Figure 11c).

Discussion

The presence of aminoacid transporters in podocytes has been known for some time [4], whereas drug transport has been largely investigated only in tubular cells [5]. As a basis for the present experiments, we speculated that substances which are harmful to the podocyte, such as Puromycin Aminonucleoside (PA), require a drug transporter system to enter and damage the cell.

The membrane transporters OATLP1 and mOCTL1 have been described in podocytes, and have been shown to contribute to trans-epithelial molecular transfer in these cells [2,3]. More recently, Xia e al. [6] suggested that PA uses a membrane transporter to enter the podocyte, and our expression data demonstrate that, besides the organic cation transporter PMAT identified by these authors, podocytes do express and utilize other transporters for which Penicillin G is a known substrate. Further support to our results comes from a series of microarray expression data obtained from mouse primary podocytes or mouse podocyte cell lines, publicly available as GEO data sets (for instance: GSM253173, GSM253174, and GSM833242, GSE17145, and GSE39441). They show that podocytes indeed express a complete

Figure 6. Transporter gene expression in human and rat podocytes. Results from RT-PCR and QRT-PCR analysis of membrane transporters in human cell lines (a,b) and primary rat podocytes (c,d). (a) RT-PCR analysis of human cell lines; P = human podocytes, N SHSY-5Y = neuroblastoma cells; I Caco2 = colon cancer cells. (b) QRT-PCR analysis of membrane transporters using the same primers in human podocytes. (c) RT-PCR analysis of primary rat podocytes; the results compare gene expression of cells obtained from three different isolation procedures (I, II, III). (d) QRT-PCR analysis of Oatps members in primary rat podocytes. Results are expressed as mean ± SEM of three independent experiments. NTC = RT-PCR negative control. doi:10.1371/journal.pone.0066159.g006
Figure 7. Membrane transporter analysis after PA treatment in human and rat podocytes. QRT-PCR analysis of membrane transporters in the human podocyte line (a,b) and primary rat podocytes (c); human podocyte gene expression was evaluated at 24 (a) and 48 hours (b) after PA treatment; (c) primary rat podocytes were evaluated after 48 hours. Results are expressed as mean ± SEM of three independent experiments. "P<0.05.
doi:10.1371/journal.pone.0066159.g007

Figure 8. Gene expression analysis of P-glycoprotein in human and rat podocytes. (a) PCR analysis of MDR1 in human podocytes. (b) PCR analysis of Mdr1a and Mdr1b in rat podocytes. NTC = RT-PCR negative control. Panel (c) shows the increase of MDR1 after 24 and 48 hours of PA incubation in human podocytes, and panel (d) displays the variation in Mdr1a and Mdr1b expression in rat podocytes. Results are expressed as mean ± SEM of three independent experiments. "P<0.05 "P<0.001.
doi:10.1371/journal.pone.0066159.g008
Figure 9. **P-glycoprotein expression and cytoskeletal organization in primary rat podocytes.** Compared to cells maintained in control conditions (a), PA-treated (10 µg/ml for 48 hours) primary podocytes show increased expression of P-glycoprotein, which is evident by immunostaining (b) and appears significant by semi-quantitative analysis of immunofluorescence (c) (**P < 0.0001** compared to NT). PA-treated cells also display reduced synaptopodin (e) and actin expression (g) as compared to untreated cells (d,f). Scale bars = 50 um.

doi:10.1371/journal.pone.0066159.g009

Figure 10. **P-glycoprotein activity.** Panel (a) shows representative histograms of Rho 123 fluorescence variation in the human podocyte cell line after PA (10 µg/ml) or cyclosporine A (CSA) (1 µM) treatment for 48 hours or incubation with medium alone (NT). The white area in the right upper panel corresponds to the autofluorescence region (AU). The values (P) in the figure indicate the percentage of fluorescent cells. Panels b) and c) illustrate PA and CSA effects on Rho 123 exit from the cells. Results are expressed as mean ± SD of three independent experiments. **P < 0.05** vs NT, ***P < 0.0001** vs NT.

doi:10.1371/journal.pone.0066159.g010
series of drug transporters of the OATP and MDR families, as well as of the OAT/OCT family.

The potent Penicillin G prevention of PA-induced increased glomerular permeability and of the accompanying harmful consequences on podocyte cytoskeletal structure can only be explained by the sharing of the same transport systems by the two substances. In line with this hypothesis, fluorescent Penicillin was observed inside the cell, while administration of Penicillin after PA was ineffective, still consistent with a cis-inhibition of the uptake mechanisms.

Drug transporter molecules have been classified into influx transporters, related to the uptake of substances into the cell, and efflux transporters, which are involved in the transport of materials outside the cell, and are typically located either at the basolateral or the apical membrane in polarized cells [17].

The OATP transporters have been considered key determinants in the cellular uptake of many endogenous and exogenous chemicals and are expressed in various tissues [17,18]. They were long considered only transporters of organic anions, but have also been shown capable of transporting cation, neutral, zwitterionic as well as anionic compounds [17]. Recently, the OATP family has been identified as the main transporter of Penicillin G in humans [19].

The proton-coupled oligopeptide transporters PEPT1 and PEPT2 have a significant role in conservation and regulation of peptide-bound amino acids and also in the absorption, availability and efficacy of a variety of peptidomimetic drugs, such β-lactam antibiotics [1].

Our results show that the mRNA of components of the OATP/Oatp families, and at a much lesser extent those of the PEPT family, are expressed by both human and rat podocytes.

**Figure 11. OATPs and P-glycoprotein blockade.** a) Inhibition of OATPs by cyclosporine. Incubation of cells with vehicle (30 min), followed by fluorescent penicillin (30 min) (NT) results in a diffuse cytoplasm fluorescent signal indicating that penicillin has entered the cell (left panel). If cyclosporine (CYCLO) is added before penicillin (right panel), most cells are negative, indicating the blockade of influx transporters (***P<0.0001 vs NT). b) Inhibition of OATPs by rifampicin. The left image represents an example of control cells incubated with vehicle followed by penicillin, showing entrance of the antibiotic as witnessed by fluorescent cytoplasm signal. On the right, 10 uM rifampicin is able to inhibit the entry of penicillin, and cells do not contain fluorescent material (**P<0.001). c) P-glycoprotein blockade by cyclosporine. The left image shows representative cells incubated with fluorescent penicillin for 30 min, followed by vehicle for additional 30 min. At this time point, penicillin has almost completely left the cells, which are mostly negative by immunofluorescence. On the right, the image shows cells incubated with fluorescent penicillin for 30 min, followed by cyclosporine for additional 30 min. Retention of fluorescence indicates the blockade of efflux transporters by cyclosporine (##P<0.005). Graphs show the results of digital measurement of fluorescent intensity, obtained from three different experiments and on 100 cells/experiment. Results are expressed as mean ± SEM. Bar = 50 um. doi:10.1371/journal.pone.0066159.g011
Expression of OATP members is affected by PA treatment, both in vitro and in vivo. In contrast to podocytes, renal tubular cells handle Penicillin G mainly by the OAT3 transporter, and accordingly, Oat3 knockout mice exhibit altered clearance and distribution of the antibiotic [20]. An exact homology between OATP transporters in humans and Oatp transporters in rodents does not exist, and several components of this transport family are still unknown. Rat Oatp1 and Oatp2 are abundantly expressed in liver and kidney and much less in the brain, whereas Oatp3 is absent in the liver but highly expressed in the kidney [21]. According to our data, podocytes seem to express both Oatp1 and Oatp2, but not Oatp3. Human OATPE and rat OatpE have an overall aminoacid sequence homology of 72.6% and have been found in the retina [22]. In contrast, the expression of Oatp4c1 was described specifically in rat glomeruli [23], in agreement with our data.

Concerning the efflux transporters, Kim et al. [17] showed that a number of OATP transporters share drug substrates with certain efflux transporters, such as P-glycoprotein (MDR1), and this co-expression is described in several organs involved in drug disposition such as the liver, the intestine, and kidney tubular cells, as well as in barrier systems, such as the blood brain barrier. P-glycoprotein acts as a membrane-bound, ATP-consuming drug efflux pump that actively extrudes a variety of structurally unrelated compounds across the plasma membrane as a defense mechanism [1]. Thus, the coordinated activity between an OATP influx transporter and an efflux transporter may determine the net cellular drug entry or efflux of shared substrates [17]. Functionally, two different types of P-glycoprotein have been described, but only class I has been related to drug transport [24]. Humans carry a single class I group gene (MDR1, or ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member 1), while rodents carry two class I genes (mdr1a and mdr1b) [1]; all encoded proteins are capable of drug transport, and Penicillin G is their main substrate [25].

We discovered a significant expression of the genes encoding P-glycoprotein in human and rat podocytes, and, similarly to OATP/Oatp molecules, their expression changed after PA treatment. In vitro, we could also confirm increased extrusion activity after PA treatment, which could be an important mechanism of protection from pathological insults, albeit not podocyte-specific, because mesangial cells have been shown to possess this protein as well [25].

Our studies with specific inhibitors of confirm that both influx and efflux transporters are actively engaged by Penicillin G on the podocyte surface. Therefore, based on results obtained in this study, we can summarize our working hypothesis as represented in Figure 12: podocytes constitutively express specific membrane transporters which regulate small solute passage across the membrane and maintain cellular homeostasis. For example, low dosages of Penicillin G are dealt by these transporters and podocytes do not exhibit morphological and molecular changes. Due to its chemical characteristics, PA uses the same membrane transporters as Penicillin G to enter podocytes, but PA entry causes podocyte damage and variation of expression of the transporters themselves. Instead, when membrane transporters are

Figure 12. Proposed working model. a) In physiological conditions, influx and efflux transporters deal with small solutes and contribute to the maintenance of podocyte structure. b) Low doses of Penicillin G use influx and efflux transporters and do not cause podocyte damage. c) Entrance of PA causes podocyte damage. In addition, cells incubated with PA display changes of expression of transporters, especially intense for efflux molecules. d) Engagement of influx transporters by Penicillin prevents the entrance of PA, that cannot exert its damaging effects on the cell. doi:10.1371/journal.pone.0066159.g012
already engaged by Penicillin G, PA entry is blocked and cell damage is prevented.

In conclusion, our study has demonstrated the existence and function of some influx and efflux membrane drug transporters on podocytes and their modification in response to PA. Further research is certainly needed to completely clarify their function, which could be relevant for cell pathophysiology and the choice of treatment for glomerular diseases. Considering that membrane transporters are involved in drug metabolism, we believe that specific polymorphisms of these molecules may be relevant to drug response in nephrotic syndrome.

References

1. Tramonti G, Xie P, Wallner EL, Danesh FR, Kanwar YS (2006) Expression and functional characteristics of tubular transporters: P-glycoprotein, PEPT1, and PEPT2 in renal mass reduction and diabetes. Am J Physiol Renal Physiol 291: F972–F980.

2. Jung SM, Lee WK, Kwak JO, Jung AV, Park J, et al. (2006) Identification of novel murine organic anion transporter like protein 1 (OATLP1) expressed in the kidney. Exp Mol Med 38: 485–493.

3. Lee WK, Hwang JS, Yun CH, Cha SH (2007) Identification of a kidney-specific mouse organic cation transporter like-1 (mOCTL1). Exp Mol Med 39: 785–795.

4. Gloy J, Reitinger S, Fisher KG, Schreiber R, Boucherot A, et al. (2000) Amino acid transport in podocytes. Am J Physiol Renal Physiol 278: F999-F1005.

5. Roeh Ramel F, De Broe E (2003) Renal handling of drugs and xenobiotics. Clinical nephrotoxins: renal injury from drugs and chemicals. Dordrecht: Kluwer p. 21–46.

6. Xia L, Zhou M, Kalhorn TF, Ho HT, Wang J (2009) Podocyte-specific expression of organic cation transporter PMAT: implication in puerarin amino nucleoside nephrotoxicity. Am J Physiol Renal Physiol 296: F1307-F1313.

7. Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, et al. (2008) Triptolide protects podocytes from puerarin amino nucleoside induced injury in vivo and in vitro. Kidney Int 74: 596–612.

8. Savin VJ, Sharma R, Lovell HV, Welling DJ (1992) Measurement of albumin reflection coefficient using isolated rat glomeruli. J Am Soc Nephrol 3: 1260–1269.

9. McCarthy ET, Sharma M, Savin VJ (2010) Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 5: 2115–2121.

10. Carraro M, Macini W, Artero M, Zennaro C, Faccini L, et al. (2001) Albumin permeability in isolated glomeruli in incipient experimental diabetes mellitus. Diabetologia 44(1): 143–50.

11. Candido R, Carraro M, Fior F, Artele ML, Zennaro C, et al. (2005) Glomular permeability defect in hypertension is dependent on renin angiotensin system activation. Am J Hypertens 18(8): 844–50.

12. Carraro M, Zennaro C, Artero M, Candiano G, Ghioggeri GM, et al. (2004) The effect of proteinase inhibitors on glomerular albumin permeability in vitro by serum from patients with idiopathic focal segmental glomerulosclerosis. Nephrol Dial Transplant 19(3): 1609–75.

Acknowledgments

The authors thank Milan Clai for technical support, Dr Barbara Dapas for contribution to gene expression studies, and Dr Giovanni Camussi for providing the human podocyte cell line.

Author Contributions

Conceived and designed the experiments: CZ MPR LP MS ET MC CT. Performed the experiments: CZ MS ET MC. Analyzed the data: CZ MPR LP ET MA. Contributed reagents/materials/analysis tools: CZ MS VDM MC. Wrote the paper: CZ MPR LP MA CT MC. Revision of manuscript after reviewers comments: CZ MPR MA.